Rep. Jared Moskowitz Sells West Pharmaceutical Services, Inc. (NYSE:WST) Shares

Representative Jared Moskowitz (D-Florida) recently sold shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on December 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in West Pharmaceutical Services stock on November 8th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Atmos Energy (NYSE:ATO) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Elevance Health (NYSE:ELV) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 11/8/2024.
• Sold $50,001 – $100,000 in shares of Seacoast Banking Co. of Florida (NASDAQ:SBCF) on 11/8/2024.

West Pharmaceutical Services Stock Down 0.9 %

WST stock opened at $319.27 on Wednesday. The company’s 50 day moving average is $311.01 and its two-hundred day moving average is $311.66. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. The stock has a market cap of $23.12 billion, a P/E ratio of 47.37, a PEG ratio of 24.47 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.35. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. The company had revenue of $746.90 million for the quarter, compared to the consensus estimate of $709.62 million. During the same period last year, the firm posted $2.16 EPS. West Pharmaceutical Services’s revenue for the quarter was down .1% on a year-over-year basis. Research analysts expect that West Pharmaceutical Services, Inc. will post 6.64 earnings per share for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 20th. Investors of record on Wednesday, November 13th were paid a $0.21 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.84 dividend on an annualized basis and a yield of 0.26%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.20. West Pharmaceutical Services’s payout ratio is currently 12.46%.

Insiders Place Their Bets

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 703 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $310.40, for a total value of $218,211.20. Following the completion of the transaction, the vice president now owns 1,253 shares in the company, valued at $388,931.20. This represents a 35.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.53% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of large investors have recently made changes to their positions in WST. Northwest Investment Counselors LLC acquired a new position in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $30,000. Crewe Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 71 shares during the last quarter. Brooklyn Investment Group purchased a new stake in West Pharmaceutical Services during the 3rd quarter worth about $41,000. Quest Partners LLC raised its stake in West Pharmaceutical Services by 5,633.3% in the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock valued at $57,000 after purchasing an additional 169 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of West Pharmaceutical Services by 332.1% during the second quarter. Blue Trust Inc. now owns 242 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 186 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2025. Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the Democratic primary scheduled on August 20, 2024. Moskowitz resigned his state House seat on January 11, 2019, to head the state’s Division of Emergency Management. Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.